این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Research in Medical Sciences، جلد ۱۷، شماره ۰۳، صفحات ۰-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Evaluation of intravitreal injection of bevacizumab (Avastin) in treatment of diabetic macular edema
چکیده انگلیسی مقاله Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 BACKGROUND : Diabetic macular edema (DME) is the most common cause of reduced vision in diabetic patients. With regards to its prevalence and its severe morbidity, attention to new methods of treatment like anti-vascular endothelial growth factor (VEGF) therapy is of great importance. Therefore, this study aimed to evaluate the efficacy of intravitreal injection of bevacizumab (Avastin) in the treatment of diabetic macular edema. METHODS : This prospective clinical trial was conducted on patients with DME who referred to Feiz Hospital, Isfahan, Iran, during 2007-8. The subjects were selected using simple sampling method. Eligible patients underwent a complete ophthalmic examination including optical coherence tomography (OCT) before injection. The treatment was performed through 3 intravitreal injections of 1.25 mg Avastin. There was a 1-month interval between very two injections. A second OCT was obtained 4 weeks after the last injection and the changes in macular thickness were compared using statistical analyses. RESULTS : This study was conducted on 52 eyes of 28 patients (17 men and 11 women) with the mean age of 62.60 ± 7.80 years (range: 45-80 years). The mean macular thickness increased from 259.19 ± 75.9 microns before injections to 265.94 ± 109.40 after 3 injections (p = 0.48). In case to case comparisons, macular thickness reductions were observed in 31 cases from 2 to 74 microns (mean: 24.60 ± 20.85). In 21 cases on the other hand, macular thickness increased from 1 to 324 microns (mean: 52 ± 88.20). Macular thickness before injection was 261.22 ± 77.79 microns in men and 255.95 ± 74.67 in women (p = 0.81). After injections, the values changed to 276.44 ± 122.79 microns in men and 249.15 ± 83.94 in women (p = 0.34). CONCLUSIONS : Intravitreal Avastin is not effective in reducing macular thickness after 4 weeks of injection. In contrast, according to other studies, it seems to be temporarily effective. Therefore, it is better to be combined with other routes of therapy, e.g. laser and intravitreal steroid, in the management of DME. KEYWORDS : Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 Avastin; Bevacizumab; Intravitreal Injection; Diabetes Mellitus; Diabetic Macular Edema; Optical Coherence ToMography
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله حسن رزمجو | hassan razmju
professor of ophthalmology, isfahan eye research center, isfahan university of medical sciences. isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

محمد رضا اخلاقی | mohamad reza akhlaghi
assistant professor of ophthalmology, isfahan eye research center, isfahan university of medical sciences. isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

مهدی توکلی | mehdi tavakoli
resident of ophthalmology, isfahan eye research center and student research committee, school of medicine, isfahan university of medical sciences. isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

نشانی اینترنتی http://jrms.mui.ac.ir/index.php/jrms/article/view/7801
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/218/article-218-331012.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات